European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Humira (adalimumab), a popular immunosuppressive medication, and its 22 biosimilars are largely absent from the formularies of Cigna's Express Scripts, CVS Caremark and UnitedHealth Group's Optum Rx.

As a medication vital for improving patient outcomes, Humira's high cost presents employers with the challenge of balancing financial considerations with the opportunities offered by biosimilars ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

Since we rolled out Connect 360 Autoimmune in 2023, we’ve transitioned over 90% of our members to the biosimilar, Yusimry, and lowered Humira spend for clients by 90%.” In addition to the ...

That changed when CVS Health removed Humira from its list of covered drugs and more patients switched to a biosimilar in three weeks than had in the prior 15 months. CVS, which owns a pharmacy ...